SkinVision

Amsterdam, Netherlands All Netherlands companies → — Founded 2011

Point-of-Care Diagnostics Specialty-Focused AI

Series A

Website Claim this company

Products

SkinVision

Dermatology AI

SkinVision is an AI-powered smartphone app that helps users assess skin cancer risk factors and track moles, guiding them on when to seek professional medical advice.

Paid

See all 1 product →

About SkinVision

SkinVision is a health technology company that leverages artificial intelligence (AI) to provide a clinically validated solution for the early recognition and tracking of common forms of skin cancer, including melanoma, basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and precancerous actinic keratosis. The mobile application allows individuals to take photos of their skin lesions, which are then analyzed by a proprietary algorithm to provide an immediate risk indication (low, low with symptoms, or high risk) and recommendations for next steps, including whether to seek professional medical advice.

For physicians, SkinVision serves as a valuable digital triage and monitoring tool, aiming to support the current healthcare system by directing appropriate patients to dermatologists while potentially reducing unnecessary referrals. Clinical studies have demonstrated the app’s high sensitivity, with recent validations showing levels around 90% for detecting the three most common forms of skin cancer, and a reported sensitivity of 95% in some studies, which is often cited as being higher than that of general practitioners and even some dermatologists. The platform also facilitates patient engagement by enabling them to track changes in their skin over time and share a personal archive of images with their healthcare providers, thereby improving efficiency and aiding in timely diagnosis and treatment.

SkinVision is a CE-marked medical device (EU MDR Class IIa) and is ISO certified for information security and medical device quality management, underscoring its commitment to regulatory compliance and data security. The company actively collaborates with medical experts, researchers, and institutions, and partners with health insurers and healthcare organizations to integrate its technology into broader preventive care platforms.

Focus Areas

Early detection of skin cancer AI-powered digital dermatology mobile health preventative care risk assessment melanoma squamous cell carcinoma basal cell carcinoma actinic keratosis

Business Intelligence

Technology

AI-powered algorithms, machine learning (Convolutional Neural Networks, Support Vector Machines), image processing (edge detection, segmentation), fractal geometry, mobile application (iOS/Android), cloud-native

What Physicians Need to Know

Specialization: Early Detection of Skin Cancer

SkinVision specializes in the early detection of common skin cancers, including melanoma, squamous cell carcinoma, basal cell carcinoma, and precancerous actinic keratosis, using AI-powered digital dermatology via a mobile application.

Key Differentiator: Clinically Validated & Certified AI

The core of SkinVision's offering is its clinically validated AI algorithm, developed in collaboration with leading dermatologists and research teams. It is a CE-certified medical device (EU MDR Class IIa), signifying high standards for safety and reliability.

Key Differentiator: High Accuracy & Triage Efficiency

The app's algorithm demonstrates high sensitivity (around 90% or higher) in detecting skin cancer, aiming to identify more cases than traditional self-assessment or general practitioner methods. This supports efficient triage, helping to direct high-risk patients to dermatologists while reducing unnecessary visits for low-risk cases.

Technology Stack: AI/Machine Learning

SkinVision's technology is powered by machine learning and deep learning, with its algorithm continuously improving by learning from a vast database of over 3.5 million skin spot images, including 200,000 images trained and validated by dermatologists.

Technology Stack: Mobile & Data Infrastructure

The service is delivered through native iOS and Android mobile applications. For data management and analytics, SkinVision utilizes an Amazon Redshift data warehouse, with Stitch for data integration and Looker for robust data governance, analysis, and visualization.

Physician Standout: Enhanced Patient Engagement & Preventative Care

SkinVision empowers patients to actively participate in their preventative skin health by performing regular self-checks and monitoring changes over time. This can lead to earlier detection and intervention, improving patient outcomes.

Physician Standout: Support for Healthcare System Efficiency

By providing a reliable risk indication, SkinVision helps alleviate pressure on healthcare systems and dermatologists by improving the quality of referrals and potentially reducing unnecessary consultations, allowing physicians to focus on cases that require their expertise.

Physician Tip

For physicians, it's crucial to understand that SkinVision is a *screening tool* providing a *risk indication*, not a definitive diagnosis. Encourage patients to use it for consistent self-monitoring and to bring their saved images and risk assessments to appointments for a more informed consultation. This tool can significantly aid in prioritizing patients and improving the efficiency of dermatological referrals by identifying potentially high-risk lesions early. It serves as a valuable adjunct to traditional clinical examination, not a replacement.

SkinVision has established partnerships with numerous health insurance providers globally, enabling reimbursement and broader access for millions of users. The company also collaborates with academic institutions and dermatologists for ongoing clinical validation and algorithm refinement. While direct Electronic Medical Record (EMR) integrations (e.g., Epic, Cerner) are noted as a slower development in the broader dermatology tech landscape, SkinVision's B2B2C model with insurers and its focus on improving referral pathways suggest potential for future system-level integrations.

Products by SkinVision

1 product in the directory

SkinVision

Dermatology AI

SkinVision is an AI-powered smartphone app that helps users assess skin cancer risk factors and track moles, guiding them on when to seek professional medical advice.

Paid

What the Web Says

SkinVision is an app that uses artificial intelligence and, in some cases, dermatologists, to assess the risk of skin lesions and moles for skin cancer. It aims to help users monitor their skin and provide an early warning system, though it explicitly states it is not a diagnostic tool and does not replace professional medical advice. The app has received mixed reviews regarding its accuracy and pricing model, but many users appreciate its role in prompting timely dermatologist visits.

Overall: Mixed

Strengths

Easy to use and user-friendly interface.
Provides quick risk assessments for skin lesions.
Helps users monitor changes in moles over time and set reminders.
Can prompt users to seek professional medical attention, leading to early diagnosis.
Backed by research and clinically tested, with reported high sensitivity in some studies.
Offers peace of mind for users concerned about skin spots.

Limitations

Not a diagnostic tool and does not replace a dermatologist's visit.
Concerns about false positives, leading to unnecessary worry or doctor visits.
Some studies suggest its sensitivity and specificity may be overestimated and lower than advertised.
Can be difficult to photograph certain areas of the body, and the front camera is not supported for quality reasons.
Paid app with some users feeling it's expensive or doesn't offer a free trial as advertised.
Some users reported discrepancies between AI assessment and professional evaluation.

Based on reviews from: The Medical Futurist, Apple App Store, Reddit, AJMC, Beauty Tech Derm, Google Play Store, Live Forever Club, Vice Magazine, Trustpilot

Last updated: 2026-08-11

Videos

News, demos, and interviews about SkinVision.

Loading videos...

Videos load interactively. If none appear, search YouTube for SkinVision →

View all on YouTube

Press & Coverage

PR Newswire UK

SkinVision Pro Launches Globally at HLTH Europe: AI-powered Skin Health Platform Connected To Healthcare Providers

SkinVision launched SkinVision Pro at HLTH Europe, a platform that connects AI-powered skin health assessments directly to medical practices, providing doctors with structured information before consultations. The service is CE-marked as a Class IIa medical device and has shown promising early real-world data in Dutch primary care.

2026-06

SkinVision

SkinVision Collaborates on Pivotal Trial to Improve Access to Dermatology Care in the United States

SkinVision announced a research collaboration with Mayo Clinic to conduct a pivotal trial required by the U.S. FDA, aiming to support the company's U.S. regulatory pathway and expand access to AI-powered skin health guidance. This collaboration is a significant scientific and regulatory milestone for SkinVision.

2026-03

SkinVision

SkinVision Earns Europe's Top Medical Certification for AI-Powered Skin Cancer Detection

SkinVision, an AI-powered medical device, achieved the higher Class IIa certification under the EU Medical Device Regulation (MDR), making it the first AI-powered medical device to receive this top European medical certification. This certification applies to all medical devices in the EU and sets a new standard for safe, AI-powered health tools.

2025-08

Management Today

From wellness to medical device: SkinVision raises the bar for AI in healthcare

SkinVision's achievement of the EU MDR Class IIa certification signifies its transition from a 'health/wellness' app to a certified medical device, demonstrating that AI in healthcare can meet the highest standards for safety, effectiveness, and trust. This certification is recognized in several markets aligning with EU medical device regulations.

2025-10

NL Times

Rising use of skin cancer apps in Netherlands aids melanoma detection

Skin cancer detection apps, particularly SkinVision, are seeing increased usage in the Netherlands, where skin cancer is the most common and fastest-growing type. SkinVision has over 1 million users in the Netherlands, with the number of skin checks increasing by 24-34% annually over the past five years.

2026-08

Rabobank

SkinVision helps reduce healthcare waiting lists with AI-powered skin cancer checks

SkinVision is expanding into the US healthcare market with support from Rabobank's Startup & Scale-up team, which is providing a three million euro financing round. The company aims to reduce skin cancer deaths globally by 50% through its AI-driven app, which provides risk assessments for skin lesions.

2026-04

News-Medical.Net

SkinVision algorithm detects 95% of skin cancer, study finds

A study published in the Journal of the European Academy of Dermatology and Venereology (JEADV) found that the SkinVision algorithm has a high sensitivity of 95.1% in detecting common forms of skin cancer, making it a valuable tool for early detection.

2019-09

Halldale Group

Skin cancer app SkinVision raises $7.6M

SkinVision secured $7.6 million in funding from existing shareholders LEO Pharma, PHS Capital, and new impact investors to support its mission of early and accurate skin cancer recognition. This funding will help the company expand its insurance provider partnerships and reach its goal of saving 250,000 lives by 2027.

2019-01

Frequently Asked Questions

How does SkinVision's AI-powered digital dermatology solution assist in the early detection and risk assessment of various skin cancers?

SkinVision utilizes a proprietary AI algorithm, trained on a vast database of dermatologist-reviewed images, to analyze smartphone photos of skin lesions. It provides an immediate risk indication (low, low with symptoms, or high) for common skin cancers like melanoma, basal cell carcinoma, squamous cell carcinoma, and pre-cancerous actinic keratosis, guiding users on whether to seek professional medical advice.

What is the clinical validation and regulatory compliance status of the SkinVision app, particularly for healthcare administrators considering its integration?

SkinVision is a CE-certified medical device app (EU MDR Class IIa), demonstrating adherence to stringent European medical device regulations for safety and reliability. The app has been clinically validated with a reported sensitivity of 95% for detecting skin cancer and is built using certified quality and security systems (ISO 13485 and ISO 27001).

What types of partnerships does SkinVision engage in with healthcare providers and insurers, and how does this impact accessibility and preventative care programs?

SkinVision partners with numerous health insurers and employers globally, enabling free access to its service for millions of members, thereby promoting preventative skin cancer screening. These collaborations aim to integrate mobile health into broader preventative care strategies, reducing pressure on healthcare systems by facilitating early risk assessment.

How does SkinVision's pricing model work for healthcare organizations or individual physicians, and what support is available for professional users?

While individuals can purchase single checks or subscription plans directly, SkinVision primarily offers its services through partnerships with health insurers and employers, often providing free access to their members. The app serves as a risk assessment tool, not a diagnosis, and supports healthcare professionals by guiding patients to appropriate follow-up care, potentially streamlining referrals.

What is SkinVision's current status regarding availability and regulatory approval in the United States market?

SkinVision is not yet available in the United States, but the company is actively pursuing FDA clearance. They have initiated a research collaboration with Mayo Clinic to conduct a pivotal trial, aiming to generate robust clinical evidence to support their U.S. regulatory pathway.

What is the company's stability and long-term vision, particularly concerning its mission to reduce skin cancer mortality?

Founded in 2012 and headquartered in Amsterdam, SkinVision has a solid history, having performed over 6 million skin checks for more than 3 million users worldwide. The company's mission is to reduce skin cancer-related deaths by 50% and save 250,000 lives by 2028, with Rabobank supporting its international growth, including expansion into the US market.

Related Companies

Suggest an Edit → | Report an issue